PANLAR consensus statement on biosimilars
Sérgio Cândido Kowalski, J. A. Benavides, P. A. B. Roa, Claudio Galarza-Maldonado et autres
INTRODUCTION: Biologics have improved the treatment of rheumatic diseases, resulting in better outcomes. However, their high cost limits access for many patients in both North America and Latin America. Following patent expiration for biologicals, the availability of biosimilars, which typically are less …
br, ec, mx, py, pa, gt, us, bo, cr, cl, do, ni, ca, ve (code pays fourni par la source)
18 citations
Clinical Rheumatology